SRX Pharmacology

SRX Pharmacology / 2010 / Article

Clinical Study | Open Access

Volume 2010 |Article ID 715414 | 4 pages | https://doi.org/10.3814/2010/715414

Sustain Released Bupropion in the Treatment of Tricotillomania: Outpatient Follow Up Survey

Received15 Oct 2009
Accepted24 Nov 2009
Published24 Jan 2010

Abstract

Objectives. Tricotillomania (TTM) is more common than expected. SSRI's are the treatment of choice in TTM. However, response rates are lower with SSRI's. The aim of our study is to explore other pharmacological interventions. Materials and Methods. Nine female TTM patients with SSRI treatment failure were included. Sample was treated with bupropion SR up to 450 mg/day. Results. Six out of nine patients responded well to bupropion SR. Massachusetts General Hospital Hair Pulling Scale (MGH) demonstrated a significant improvement at the twelve week point (f: 32.3, power: 1, lambda: 97.1, P<.0001) and the response rates remained stable at sixteen-month follow up visit. Conclusions. Bupropion SR could be an alternative pharmacological treatment for TTM. Larger samples with double blind placebo controlled design are needed to confirm our preliminary report.

References

  1. G. A. Christenson, T. B. MacKenzie, and J. E. Mitchell, “Adult men and women with trichotillomania: a comparison of male and female characteristics,” Psychosomatics, vol. 35, no. 2, pp. 142–149, 1994. View at: Google Scholar
  2. ICD-10 Classification of Mental & Behavioral Disorders, World Health Organization, 1992.
  3. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 1994.
  4. D. A. Regier, W. E. Narrow, and D. S. Rae, “The epidemiology of anxiety disorders: the epidemiologic catchment area (ECA) experience,” Journal of Psychiatric Research, vol. 24, pp. 3–14, 1990. View at: Publisher Site | Google Scholar
  5. E. Hollander, S. Kim, S. Khanna et al., “Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues,” CNS Spectrums, vol. 12, pp. 5–13, 2007. View at: Google Scholar
  6. E. Hollander and C. M. Wong, “Obsessive-compulsive spectrum disorders,” Journal of Clinical Psychiatry, vol. 56, pp. 3–6, 1995. View at: Google Scholar
  7. S. Lochner, S. Seedat, P. du Toit et al., “Obsessive compulsive disorder and tricotillomania: a phenomenological comparison,” BMC Psychiatry, vol. 5, article 2, 2005. View at: Google Scholar
  8. S. E. Stewart, M. A. Jenike, and N. J. Keuthen, “Severe obsessive-compulsive disorder with and without comorbid hair pulling: comparisons and clinical implications,” Journal of Clinical Psychiatry, vol. 66, no. 7, pp. 864–869, 2005. View at: Google Scholar
  9. S. R. Chamberlain, N. A. Fineberg, A. D. Blackwell, L. Clark, T. W. Robbins, and B. J. Sahakian, “A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania,” Neuropsychologia, vol. 45, no. 4, pp. 654–662, 2007. View at: Publisher Site | Google Scholar
  10. A. van Minnen, K. A. L. Hoogduin, G. P. J. Keijsers, I. Hellenbrand, and G.-J. Hendriks, “Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study,” Archives of General Psychiatry, vol. 60, no. 5, pp. 517–522, 2003. View at: Publisher Site | Google Scholar
  11. N. J. Keuthen, R. L. O'Sullivan, P. Goodchild, D. Rodriguez, M. A. Jenike, and L. Baer, “Retrospective review of treatment outcome for 63 patients with trichotillomania,” American Journal of Psychiatry, vol. 155, no. 4, pp. 560–561, 1998. View at: Google Scholar
  12. K. M. Gadde, R. H. Wagner, II, K. M. Connor, and M. S. Foust, “Escitalopram treatment of trichotillomania,” International Clinical Psychopharmacology, vol. 22, no. 1, pp. 39–42, 2007. View at: Publisher Site | Google Scholar
  13. G. A. Christenson, T. B. Mackenzie, J. E. Mithchell et al., “A placebo controlled double-blind crossover study of fluoxetine in Tricotillomania,” American Journal of Psychiatry, vol. 148, pp. 1566–1571, 1991. View at: Google Scholar
  14. M. H. Bloch, A. Landeros-Weisenberger, P. Dombrowski et al., “Systematic review: pharmacological and behavioral treatment for trichotillomania,” Biological Psychiatry, vol. 62, no. 8, pp. 839–846, 2007. View at: Publisher Site | Google Scholar
  15. W. R. Yates, J. Mitchell, A. J. Rush et al., “Clinical features of depressed outpatients with and without co-occurring general medical conditions in STARD,” General Hospital Psychiatry, vol. 26, no. 6, pp. 421–429, 2004. View at: Publisher Site | Google Scholar
  16. B. W. Palmer, P. V. Jeste, and J. I. Scheikh, “Anxiety disorders in the elderly: DSM-IV and other barriers to diagnosis and treatment,” Journal of Affective Disorders, vol. 46, pp. 183–190, 1997. View at: Google Scholar
  17. J. A. Himle, P. S. Bordnick, and B. A. Thyer, “A comparison of trichotillomania and obsessive-compulsive disorder,” Journal of Psychopathology and Behavioral Assessment, vol. 17, no. 3, pp. 251–260, 1995. View at: Publisher Site | Google Scholar
  18. S. M. J. Hemmings, C. J. Kinnear, C. Lochner et al., “Genetic correlates in trichotillomania—a case-control association study in the South African Caucasian population,” Israel Journal of Psychiatry and Related Sciences, vol. 43, no. 2, pp. 93–101, 2006. View at: Google Scholar
  19. M. Rubinstein, T. J. Phillips, J. R. Bunzow et al., “Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine,” Cell, vol. 90, no. 6, pp. 991–1001, 1997. View at: Publisher Site | Google Scholar
  20. J.-H. Lee, H.-T. Kim, and D.-S. Hyun, “Possible association between serotonin transporter promoter region polymorphism and impulsivity in Koreans,” Psychiatry Research, vol. 118, no. 1, pp. 19–24, 2003. View at: Publisher Site | Google Scholar
  21. D. D. Dougherty, R. Loh, M. A. Jenike, and N. J. Keuthen, “Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?,” Journal of Clinical Psychiatry, vol. 67, no. 7, pp. 1086–1092, 2006. View at: Google Scholar
  22. A. De Sousa, “An open-label pilot study of naltrexone in childhood-onset trichotillomania,” Journal of Child and Adolescent Psychopharmacology, vol. 18, no. 1, pp. 30–33, 2008. View at: Publisher Site | Google Scholar
  23. C. Lochner, S. Seedat, D. J. H. Niehaus, and D. J. Stein, “Topiramate in the treatment of trichotillomania: an open-label pilot study,” International Clinical Psychopharmacology, vol. 21, no. 5, pp. 255–259, 2006. View at: Publisher Site | Google Scholar
  24. M. Hamilton, “The assessment of anxiety states by rating,” The British Journal of Medical Psychology, vol. 32, no. 1, pp. 50–55, 1959. View at: Google Scholar
  25. M. Hamilton, “A rating scale for depression,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 23, pp. 56–62, 1960. View at: Google Scholar
  26. S. Spiga, A. Lintas, and M. Diana, “Addiction and cognitive functions,” Annals of the New York Academy of Sciences, vol. 1139, pp. 299–306, 2008. View at: Publisher Site | Google Scholar
  27. S. W. Clay, J. Allen, and T. Parran, “A review of addiction,” Postgraduate Medicine, vol. 120, no. 2, pp. E01–E07, 2008. View at: Publisher Site | Google Scholar
  28. M. A. Sullivan and L. S. Covey, “Nicotine dependence: the role for antidepressants and anxiolitics,” Current Opinion in Investigational Drugs, vol. 3, pp. 262–271, 2002. View at: Google Scholar
  29. S. Tardieu, Y. Poirier, J. Micallef, and O. Blin, “Amphetamine-like stimulant cessation in an abusing patient treated with bupropion,” Acta Psychiatrica Scandinavica, vol. 109, no. 1, pp. 75–77, 2004. View at: Publisher Site | Google Scholar
  30. T. Chan-Ob, N. Kuntawongse, and V. Boonyanaruthee, “Bupropion for amphetamine withdrawal syndrome,” Journal of the Medical Association of Thailand, vol. 84, no. 12, pp. 1763–1765, 2001. View at: Google Scholar
  31. F. R. Levin, S. M. Evans, D. M. McDowell, D. J. Brooks, and E. Nunes, “Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder,” Journal of Addictive Diseases, vol. 21, no. 2, pp. 1–16, 2002. View at: Publisher Site | Google Scholar
  32. N. Zwar and R. Richmond, “Bupropion sustained release. A therapeutic review of Zyban,” Australian Family Physician, vol. 31, no. 5, pp. 443–447, 2002. View at: Google Scholar
  33. D. W. Black, S. Arndt, W. H. Coryell et al., “Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study,” Journal of Clinical Psychopharmacology, vol. 27, no. 2, pp. 143–150, 2007. View at: Publisher Site | Google Scholar
  34. P. N. Dannon, K. Lowengrub, E. Musin, Y. Gonopolski, and M. Kotler, “Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study,” Journal of Clinical Psychopharmacology, vol. 25, no. 6, pp. 593–596, 2005. View at: Publisher Site | Google Scholar

Copyright © 2010 Pinhas N. Dannon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

166 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.